Short Interest in Cryoport, Inc. (NASDAQ:CYRX) Expands By 9.1%

Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 4,430,000 shares, a growth of 9.1% from the March 31st total of 4,060,000 shares. Based on an average trading volume of 445,600 shares, the days-to-cover ratio is presently 9.9 days. Approximately 9.4% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Needham & Company LLC reduced their price objective on Cryoport from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, March 13th. Stephens restated an "equal weight" rating and set a $17.00 target price on shares of Cryoport in a report on Wednesday, March 13th. UBS Group increased their target price on Cryoport from $14.50 to $17.00 and gave the company a "neutral" rating in a report on Friday, March 15th. Finally, Jefferies Financial Group initiated coverage on Cryoport in a report on Thursday, April 4th. They set a "buy" rating and a $21.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Cryoport has a consensus rating of "Hold" and an average price target of $18.63.

Cryoport Trading Down 3.7 %

NASDAQ CYRX traded down $0.62 on Tuesday, hitting $16.19. The company's stock had a trading volume of 287,148 shares, compared to its average volume of 440,648. Cryoport has a 52-week low of $9.00 and a 52-week high of $24.17. The company has a current ratio of 11.73, a quick ratio of 11.16 and a debt-to-equity ratio of 0.82. The company's 50-day simple moving average is $16.89 and its 200 day simple moving average is $15.03. The firm has a market cap of $795.90 million, a P/E ratio of -7.64 and a beta of 1.60.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.19). Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. The business had revenue of $57.26 million during the quarter, compared to analysts' expectations of $58.27 million. Research analysts predict that Cryoport will post -1.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ramkumar Mandalam sold 3,217 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $14.68, for a total transaction of $47,225.56. Following the transaction, the director now directly owns 43,187 shares in the company, valued at approximately $633,985.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Jerrell Shelton sold 3,723 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $16.35, for a total transaction of $60,871.05. Following the transaction, the chief executive officer now directly owns 636,951 shares in the company, valued at approximately $10,414,148.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ramkumar Mandalam sold 3,217 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the transaction, the director now owns 43,187 shares in the company, valued at $633,985.16. The disclosure for this sale can be found here. Insiders have sold 73,940 shares of company stock worth $1,147,538 in the last ninety days. 10.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CYRX. Natixis Investment Managers International increased its position in Cryoport by 61.5% during the 4th quarter. Natixis Investment Managers International now owns 4,536 shares of the company's stock valued at $70,000 after buying an additional 1,727 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Cryoport by 13.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company's stock valued at $157,000 after buying an additional 1,395 shares in the last quarter. WINTON GROUP Ltd bought a new position in Cryoport during the 3rd quarter valued at approximately $163,000. Pathstone Family Office LLC bought a new position in Cryoport during the 3rd quarter valued at approximately $165,000. Finally, Quantbot Technologies LP increased its position in Cryoport by 109.0% during the 3rd quarter. Quantbot Technologies LP now owns 12,838 shares of the company's stock valued at $176,000 after buying an additional 6,694 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company's stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.